相关实验视频
Updated: Jun 26, 2025

06:16
Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
Published on: May 9, 2019
7.6K
用丹诺苏马布治疗的移植患者的长期骨矿物质密度变化:与无等效对照组进行回顾性研究
Angelo Fassio1,2, Stefano Andreola3, Davide Gatti4
1Rheumatology Unit, University of Verona, Verona, Italy. angelo.fassio@aovr.veneto.it.
Calcified tissue international
|May 10, 2024
概括
代诺苏马布治疗在四年内显著增加了移植接受者 (KTR) 的骨矿物质密度 (BMD). 未经治疗的KTR经历了显著的BMD损失,突出显示了denosumab.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 整形外科 整形外科 整形外科
背景情况:
- 骨质疏松症是移植接受者 (KTRs) 的一个重大问题.
- 有限的数据存在于KTRs的骨质疏松症管理的denosumab的长期有效性.
- 骨矿物质密度 (BMD) 评估对于监测骨质疏松症进展和治疗疗效至关重要.
研究的目的:
- 研究德诺苏马布对移植受体 (KTRs) 骨矿物密度 (BMD) 的长期影响.
- 为了比较四年内用德诺苏马布治疗的KTR与未接受治疗的对照组之间的BMD变化.
主要方法:
- 一项前性研究涉及23名KTR患者,他们接受了4年的丹诺苏马布治疗 (每6个月服用60毫克).
- 为了进行比较,将23个未经处理的KTR (1:1比率) 的匹配对照组纳入其中.
- 骨矿物质密度 (BMD) 在基线和4年后使用双能X射线吸收计 (DXA) 进行评估. 血清标记物包括肌素,性酸酶 (ALP),副甲状腺激素和25-氧维生素D都被监测. 所有患者都接受和维生素D补充剂.
主要成果:
- 代诺苏马布组在4年内显著增加了腰椎 (9.0%) 和部总体 (3.8%) 的骨质量 (p < 0.001和p = 0.041).
- 没有接受治疗的小组在腰椎 (-3.0%),部 (-6.3%) 和大腿部 (-6.7%) 显著减少了骨质量 (p <0.05在所有部位).
- 在所有测量地点观察到骨质量变化的显著群体间差异. 在denosumab组,血清ALP水平显著下降. 两组之间没有发现血清肌素,低血症或急性移植拒绝率的显著差异.
结论:
- 经过四年的德诺苏马布治疗,可以有效地增加移植接受者 (KTRs) 的骨髓质量.
- 德诺苏马布治疗可以防止未经治疗的KTRs中观察到的显著的BMD损失.
- 德诺苏马布在KTR中表现出良好的安全性,没有增加低血症或急性移植排斥的风险.
相关概念视频
Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
Bone Remodeling
38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K
Osteoclasts in Bone Remodeling
2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K

